Innovative Health Care Models Prove Cost-Effective Amidst Pandemic Pressures

By HEOR Staff Writer

September 26, 2023

During the COVID-19 pandemic, hospitals faced immense pressure. Singapore was also grappling with a dengue outbreak, adding to the strain on hospital capacity. This situation led to the rapid implementation of novel care models to treat patients with acute, low-severity medical conditions.

Two of these models, the hospital-at-home (HaH) and ambulatory care team (ACT) models, were used to treat patients with dengue and chest pain respectively. The HaH model allowed patients to receive care at home, while the ACT model provided timely care in a clinic-style setting at the hospital’s emergency department.

An economic evaluation aimed to compare the personnel cost of these models with conventional hospital inpatient care. The results showed that the HaH and ACT models used less personnel time, resulting in reduced costs.

The HaH model for treating dengue was found to be slightly cheaper than conventional care, with estimated savings of 18 SGD per case. The ACT model for treating chest pain showed more significant savings, with an estimated reduction of 126 SGD per case.

These innovative health care models not only alleviate hospital pressure but also potentially reduce hospital-acquired infections, length of stay, and overall health care expenditure. However, a reliable cost analysis of these models remains a priority.

Reference url

Recent Posts

gene therapy reimbursement
Gene Therapy Reimbursement Strategies for Vision Restoration

By HEOR Staff Writer

June 12, 2026

Gene therapy reimbursement in the Netherlands has demonstrated clear clinical value since the 2021 conditional access agreement for voretigene neparvovec (Luxturna®). Five years of structured real-world use confirmed that carefully designed protocols successfully selected appropriate patients wit...
Innovative Therapies Access Portugal
Evaluating Innovative Therapies Access in Portugal

By João L. Carapinha

June 11, 2026

According to Paulo Gonçalves in the APIFARMA newsletter, Innovative Therapies Access in Portugal directs resources toward therapeutic innovation at levels substantially below feasible ambitions. Protracted authorization processes impose measurab...
Insulin Cost Policy Impact
Insulin Cost Policy Impact on Medicare Beneficiaries

By HEOR Staff Writer

June 8, 2026

The Insulin Cost Policy Impact became clear in 2023 after the Inflation Reduction Act limited out-of-pocket insulin expenses to $35 per 30-day supply for Medicare Part D beneficiaries. According to a JAMA Network study, the c...